title: [A case report of complete response to RPMI regimen for multiple lymph node metastases following rectal cancer surgery].
abstract: A 78-year old man underwent low anterior resection for Stage IIIb rectal cancer(Ra). After surgery, he underwent the Roswell Park Memorial Institute(RPMI)regimen for 6 months followed by oral UFT for 8 months. Since liver metastasis(S6)recurred 2 years and 2 months after surgery, he underwent S6 subsegmentectomy. Four years and 4 months later, he developed multiple lymph node metastases(the Virchow, paraaortic, and intrapelvic lymph nodes), for which FOLFIRI therapy was started, but converted to the RPMI regimen because of strong gastrointestinal side effects. After 3 courses of this regimen, tumor markers returned to normal, and imaging studies showed that the metastases had disappeared. This was interpreted as a complete response(CR). The patient has maintained the complete response for 1 year and 4 months since the start of the RPMI regimen.
authors.affiliation: Division of Gastroenterological and General Surgery, St. Marianna University School of Medicine.
authors.forename: Kohei
authors.initials: K
authors.lastname: Segami
authors.forename: Joe
authors.initials: J
authors.lastname: Sakurai
authors.forename: Akiyoshi
authors.initials: A
authors.lastname: Noda
authors.forename: Toshiyuki
authors.initials: T
authors.lastname: Suwa
authors.forename: Takeharu
authors.initials: T
authors.lastname: Enomoto
authors.forename: Shinjiroh
authors.initials: S
authors.lastname: Kobayashi
authors.forename: Ryoji
authors.initials: R
authors.lastname: Makizumi
authors.forename: Satoshi
authors.initials: S
authors.lastname: Tsukikawa
authors.forename: Kyoji
authors.initials: K
authors.lastname: Yamada
authors.forename: Nobuyoshi
authors.initials: N
authors.lastname: Miyajima
authors.forename: Takehito
authors.initials: T
authors.lastname: Otsubo
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000097:blood; D005472:Fluorouracil / Q000627:therapeutic use*; D006801:Humans; D002955:Leucovorin / Q000627:therapeutic use*; D008207:Lymphatic Metastasis / Q000000981:diagnostic imaging / Q000473:pathology; D008297:Male; D049268:Positron-Emission Tomography; D012004:Rectal Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000473:pathology* / Q000601:surgery; D012074:Remission Induction; D014057:Tomography, X-Ray Computed
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D002955:Leucovorin; D005472:Fluorouracil